The benefits of taking GLP-1 agonists seem to outweigh the risks, at least when taken for approved uses, according to an ...

The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...

In all, researchers found that people taking GLP-1 medications had lower risks for 42 health outcomes, including liver ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...

Novo Nordisk ( NYSE:NVO) and Eli Lilly ( NYSE:LLY) are making headlines againthis time, for potential benefits beyond weight ...

A study analyzing data from over 2 million veterans found that GLP-1 receptor agonists, popular weight-loss drugs like ...

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the ...

The Biden administration unveiled its list of 15 drugs, which include GLP-1 drugs Ozempic, Wegovy and Rybelsus, for the ...

A study by Washington University School of Medicine and the VA St. Louis Health Care System has found that GLP-1 drugs can have both health benefits and risks, including reduced risks of ...

Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...